AbbVie posts weak sales of newer drugs as Humira faces fresh competition, shares fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AbbVie (ABBV) shares slide despite revenue beat
April 27, 2023 8:55 AM EDTAbbVie (NYSE: ABBV) shares are tumbling premarket, currently down over 6% after the company reported its first-quarter earnings, which saw it report in-line profits and a revenue beat but miss sales estimates for some of its major drugs.
The company reported Q1 EPS of... More
